Sparsentan is superior to losartan in the gddY mouse model of IgA nephropathy.

Hajime NagasawaSeiji UedaHitoshi SuzukiCelia JenkinsonYusuke FukaoMaiko NakayamaTomoyuki OtsukaTeruyuki OkumaWilmelenne ClapperKai LiuMai NguyenRadko KomersYusuke Suzuki

Published in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024)

The results of this study, and in light of the results of the phase 3 PROTECT trial, provide a novel perspective and understanding of the mechanisms by which sparsentan has a beneficial renoprotective effect against IgAN compared with AT1R antagonism alone.

Keyphrases

mouse model
clinical trial
study protocol
phase iii
angiotensin ii
randomized controlled trial
open label